Clinical Trial Update: Siplizumab for Sickle Cell Disease Transplant [Phase 1, Phase 2]

View source ↗

Summary

ClinicalTrials.gov shows termination of a Phase 1/2 trial evaluating siplizumab for sickle cell disease, with results posted on 2026-02-27.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Siplizumab (siplizumab)

Snippet

Sponsor: Columbia University | Conditions: Anemia, Sickle Cell | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-27